Table 1 Characteristics of the patients
Characteristic | Total population |
|---|---|
| Â | Median (IQR) |
Age | 66 (61–76) |
BMI | 26.1 (23.6–28.3) |
| Â | N (%) |
Sex | |
 Male | 36 (61.0%) |
 Female | 23 (39.0%) |
Type of cancer | |
 Lung cancer | 16 (27.1%) |
 Bladder cancer | 15 (25.4%) |
 Kidney cancer | 11 (18.6%) |
 Uterine cancer | 5 (8.5%) |
 Pancreatic cancer | 3 (5.1%) |
 Other | 8 (13.6%) |
 Missing | 1 (1.7%) |
Type of therapy | |
 Anti-PD1 | 49 (83.0%) |
 Anti-PD-L1 | 8 (13.6%) |
 I/O combo | 2 (3.4%) |
Vaccine | |
 BNT162b2 | 41 (69.5%) |
 AZD1222 | 15 (25.4%) |
 mRNA-1273 | 3 (5.1%) |
Vaccine-related adverse events | |
 None | 37 (62.7%) |
 Fever | 1 (1.7%) |
 Pain at injection site | 11 (18.6%) |
 Fatigue | 3 (5.1%) |
 Other | 1 (1.7%) |
Comorbidities | |
 Yes | 39 (66.1%) |
 None | 11 (18.6%) |
 Missing | 9 (15.3%) |